Modes of drug delivery used to manage Parkinson's disease.
Parkinson's disease is the second most frequent neurodegenerative condition after Alzheimer's disease and with an ageing population, the burden of care will only increase. This article presents an overview of the condition, its pharmacological and care management, and novel treatment approaches.
Noble
Carolyn
C
Greater Peterborough Primary Care Partnership.
D000978:Antiparkinson Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D065098:Catechol O-Methyltransferase Inhibitors; D018450:Disease Progression; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009720:Nurse Clinicians / Q000458:organization & administration; D024802:Nurse's Role; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D018579:Patient Selection; D006113:United Kingdom / Q000453:epidemiology
D000978:Antiparkinson Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa